Zolpidem vs. Emerging Hypnotics: Neuropsychiatric Effects and Ethical Considerations

CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · Published 2026-07-16 · DOI 10.2174/0118715273442470260706171716

Authors (5)

Tawqeer Shafi, Zora Singh, Puja Gulati, Shafqat Hussain Malik, Md Moidul Islam

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Shafi, T., Singh, Z., Gulati, P., et al. (2026). Zolpidem vs. Emerging Hypnotics: Neuropsychiatric Effects and Ethical Considerations. CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS. https://doi.org/10.2174/0118715273442470260706171716

Related articles

• MicroRNAs as Molecular Modulators in Stroke: Pathogenic Mechanisms and Therapeutic Avenues · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Early Anti-CD20 and CNS Penetrant BTK Inhibition to Enhance OPC-Driven Remyelination in Multiple Sclerosis · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Neuroinflammatory and Synaptic Roles of Glial Cells in Autism SpectrumDisorder · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Redefining Parkinson’s Care: The Promise of Nanotechnology and Artificial Intelligence · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• The Effect of a Novel Antibody-based Drug, Prospekta, on Brain Electrical Activity in Mice · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Synthetic Imidazole Derivatives as Multitarget Agents in Depression:Insights into Mechanism and Therapeutic Promise · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Brigatinib in ALK-fused, Low-grade Pediatric Angiocentric Glioma withMultiple Extracranial Metastases: A Case Report · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Re-Profiling and Re-purposing of FDA-Approved AntiViral AgentsAgainst Neurological Targets of Memory and Cognition: MolecularDocking and Simulation Approach · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Therapeutic Innovations in Parkinson’s and Alzheimer’s Disease: Molecular Mechanisms and Emerging Strategies · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal
• Mitochondrial Dysfunction in Parkinson's Disease: Diagnostic andTherapeutic Advances · CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS · 2026 · Same journal